| Literature DB >> 27460397 |
Hideki Kato1, Masaomi Nangaku1, Hiroshi Hataya2, Toshihiro Sawai3, Akira Ashida4, Rika Fujimaru5, Yoshihiko Hidaka6, Shinya Kaname7, Shoichi Maruyama8, Takashi Yasuda9, Yoko Yoshida1, Shuichi Ito10, Motoshi Hattori11, Yoshitaka Miyakawa12, Yoshihiro Fujimura13, Hirokazu Okada14, Shoji Kagami15.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely initiation of appropriate treatment for aHUS. Recent clinical and molecular findings have resulted in several proposed classifications and definitions of thrombotic microangiopathy and aHUS. Based on recent advances in this field and the emerging international consensus to exclude secondary TMAs from the definition of aHUS, we have redefined aHUS and proposed diagnostic algorithms, differential diagnosis, and therapeutic strategies for aHUS.Entities:
Keywords: alternative complement pathway; atypical hemolytic uremic syndrome; eculizumab; thrombotic microangiopathy
Mesh:
Year: 2016 PMID: 27460397 DOI: 10.1111/ped.13044
Source DB: PubMed Journal: Pediatr Int ISSN: 1328-8067 Impact factor: 1.524